Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options.
Delcath Systems announced that the United Kingdom’s NICE, through the Interventional Procedures Advisory Committee, has updated its guidance for the Delcath Chemosat hepatic delivery system for melphalan in the treatment of patients with metastases in the liver from ocular melanoma.
